India Ratings and Research (Ind-Ra) has, over the last four weeks, conducted a series of webinars and exclusive investor calls to share its views on sectors and its portfolio of ratings on account of the disruption emanating from the Covid-19 outbreak and the associated policy response. The rating and research agency is now coming out in public domain by communicating its assessments at various such engagements. Chart summarises first of such assessment.
Pharmaceuticals
Evaluated 16 companies. Although some China-centric pressures have started to ease, disruptions in the logistic network coupled with gradual relaxation of the restrictions in China are likely to